For Immediate Release **February 5, 2021**

Acuitas President & CEO to Participate in Panel Led by Prestigious Gairdner Foundation

Vancouver, B.C. – On February 9, from 9 a.m. – 10 a.m. PST, Janet Rossant, President & Scientific Director of the Gairdner Foundation, will host a panel of leaders from Canadian biotech and bio pharmaceutical companies who will discuss COVID-19 treatments and vaccines. This includes Acuitas President & CEO, Dr. Thomas Madden.

Dr. Madden will discuss the Acuitas proprietary technology that is currently being used for COVID-19 vaccines. Acuitas is considered a global leader in the development of lipid nanoparticle (LNP) delivery systems for messenger RNA therapeutics. Acuitas' LNP is used in the BioNTech/Pfizer COMIRNATY® COVID-19 vaccine and other COVID-19 vaccines that are currently in clinical development.

Dr. Madden's fellow panelists at this online event include: Véronique Lecault, Co-founder and COO of Vancouver's AbCellera (www.abcellera.com) and Brian Ward, Medical Officer at Quebec City-based Medicago (www.medicago.com).

You can learn more about the panelists and register to watch this online event here: https://bit.ly/3a8l8OS.

About Acuitas Therapeutics

Founded in February 2009, Vancouver-based Acuitas Therapeutics (www.acuitastx.com) is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles. The company partners with pharmaceutical companies, biotechnology organizations and academic institutes to advance nucleic acid therapeutics to the clinical trial phase and to the marketplace. The team works with partners to develop new therapies to address unmet clinical needs based on its internationally recognized capabilities in delivery technology. Acuitas Therapeutics has agreements in place for their proprietary lipid nanotechnology to be used in the development of several COVID-19 vaccines. Other collaborators include CureVac, which initiated a Phase 2b/3 study in late 2020 and expects to request authorization for Emergency Use in the first half of 2021.

-END-